Clinical Trials Logo

Brain Metastases clinical trials

View clinical trials related to Brain Metastases.

Filter by:

NCT ID: NCT04427228 Withdrawn - Brain Metastases Clinical Trials

Single vs Multi-fraction SRS Patients on Immunotherapy

MIGRAINE
Start date: June 29, 2020
Phase: Phase 2
Study type: Interventional

This study is meant to compare different surgical approaches to brain cancer.

NCT ID: NCT04422639 Terminated - Brain Metastases Clinical Trials

Preoperative SRS/SRT vs Postoperative SRS/SRT for Brain Metastases

Start date: August 24, 2020
Phase: N/A
Study type: Interventional

This pilot study is a randomized, open-label, 2-arm active-controlled phase II clinical trial conducted at a single study site (UAMS). Subjects will be randomized to one of the 2 treatment arms and stratified by size of index lesion and number of brain metastases. The investigators will prospectively compare preoperative (neoadjuvant) SRS/SRT to postoperative (adjuvant) SRS/SRT in patients undergoing surgical resection for brain metastases. The investigators hypothesize that neoadjuvant SRS/SRT prior to surgical resection of brain metastases will result in improved freedom from Central Nervous System (CNS) events when compared to adjuvant SRS/SRT after surgical resection.

NCT ID: NCT04420598 Completed - Brain Metastases Clinical Trials

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

DEBBRAH
Start date: May 25, 2020
Phase: Phase 2
Study type: Interventional

This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial

NCT ID: NCT04415320 Recruiting - Brain Metastases Clinical Trials

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Start date: March 21, 2019
Phase: Phase 2
Study type: Interventional

To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures.

NCT ID: NCT04410367 Completed - Brain Metastases Clinical Trials

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

PURSUE
Start date: August 31, 2020
Phase: Phase 2
Study type: Interventional

An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy

NCT ID: NCT04410133 Completed - Brain Metastases Clinical Trials

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

REVELATE
Start date: October 26, 2020
Phase: Phase 3
Study type: Interventional

An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy

NCT ID: NCT04395339 Recruiting - Breast Cancer Clinical Trials

GM1 Prophylaxis for WBRT Related Cognitive Dysfunction

GLORY
Start date: May 15, 2020
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of GM1 for preventing cognitive impairment related to whole brain radiotherapy in breast cancer patients with brain metastases. And explore the clinical and molecular parameter for predicting severe cognitive impairment induced by WBRT and gaining benefit from GM1. Primary Endpoint: the change of Hopkins Verbal and Learning Test-Revised Delayed Recall,HVLT-R DR,before and after WBRT Secondary ENDPOINT: the change of Alzheimer's Disease Assessment Scale-Cognitive,ADAS-Cog before and after WBRT;severe cognitive impairment percentage and onset time; Design:204 patients will be randomly assigned to exp.group,102 cases,and 102 cases of control group.

NCT ID: NCT04365374 Recruiting - Brain Metastases Clinical Trials

Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

Start date: April 6, 2021
Phase: Phase 3
Study type: Interventional

This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.

NCT ID: NCT04358666 Recruiting - Quality of Life Clinical Trials

Evaluation of the Best Treatment in Terms of Quality of Life for Patients Having a Brain Metastasis

OPTMETACER
Start date: March 6, 2020
Phase: N/A
Study type: Interventional

Main Goal : evaluation of quality of life for patient having a brain metastasis and allowed to have either surgery and radiosurgery of the surgical site or only hypofractionned radiosurgery on the lesion. second objectives : evaluation of the local control of the disease evaluation of the overall survival interval without progression evaluation of the medico economic performance of each treatment protocol neuro cognitive evaluation at the end of the protocol

NCT ID: NCT04334863 Completed - Brain Tumor Clinical Trials

WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors

Start date: May 4, 2020
Phase: Phase 1
Study type: Interventional

In this Phase I clinical study, the investigators plan to offer investigational treatment with the novel JAK2/STAT3 inhibitor WP1066 (Moleculin Biotech, Inc.) to pediatric patients with any progressive or recurrent malignant brain tumor that is refractory to standard treatment and is without known cure.